The estimated Net Worth of Donald J Kellerman is at least $616 Тысяча dollars as of 31 March 2022. Dr Kellerman owns over 4,006 units of Zosano Pharma Corp stock worth over $31,545 and over the last 10 years he sold ZSAN stock worth over $2,226. In addition, he makes $582,223 as VP of Clinical Devel. & Medical Affairs at Zosano Pharma Corp.
Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!
Dr Kellerman ZSAN stock SEC Form 4 insiders trading
Dr has made over 3 trades of the Zosano Pharma Corp stock since 2016, according to the Form 4 filled with the SEC. Most recently he sold 4,006 units of ZSAN stock worth $841 on 31 March 2022.
The largest trade he's ever made was buying 15,920 units of Zosano Pharma Corp stock on 19 August 2016 worth over $21,014. On average, Dr trades about 1,664 units every 158 days since 2014. As of 31 March 2022 he still owns at least 56,331 units of Zosano Pharma Corp stock.
You can see the complete history of Dr Kellerman stock trades at the bottom of the page.
Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!
Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!
Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!
Dr. Donald J. Kellerman biography
Dr. Donald J. Kellerman is the VP of Clinical Devel. & Medical Affairs at Zosano Pharma Corp.
What is the salary of Dr Kellerman?
As the VP of Clinical Devel. & Medical Affairs of Zosano Pharma Corp, the total compensation of Dr Kellerman at Zosano Pharma Corp is $582,223. There are 1 executives at Zosano Pharma Corp getting paid more, with Steven Lo having the highest compensation of $756,275.
How old is Dr Kellerman?
Dr Kellerman is 66, he's been the VP of Clinical Devel. & Medical Affairs of Zosano Pharma Corp since . There are no older and 8 younger executives at Zosano Pharma Corp.
What's Dr Kellerman's mailing address?
Donald's mailing address filed with the SEC is C/O ZOSANO PHARMA CORPORATION, 34790 ARDENTECH COURT, FREMONT, CA, 94555.
Insiders trading at Zosano Pharma Corp
Over the last 10 years, insiders at Zosano Pharma Corp have traded over $5,506,679 worth of Zosano Pharma Corp stock and bought 790,627 units worth $1,835,090 . The most active insiders traders include M James Barrett, Enterprise Associates 12, L... и Steve Elms. On average, Zosano Pharma Corp executives and independent directors trade stock every 60 days with the average trade being worth of $44,258. The most recent stock trade was executed by Christine Matthews on 6 June 2022, trading 82 units of ZSAN stock currently worth $58.
What does Zosano Pharma Corp do?
Zosano Pharma Corporation is a clinical-stage biopharmaceutical company focused on developing products where rapid administration of approved molecules with established safety and efficacy profiles may provide substantial benefit to patients, in markets where patients remain underserved by existing therapies. The company's transdermal microneedle system technology consists of titanium microneedles coated with drug that are designed to enable rapid systemic administration of therapeutics to patients. Zosano's lead product candidate is Qtrypta™ (M207), which is a proprietary formulation of zolmitriptan designed to be delivered via its transdermal microneedle system technology, as an acute treatment for migraine.
What does Zosano Pharma Corp's logo look like?
Complete history of Dr Kellerman stock trades at Tonix Pharmaceuticals Corp и Zosano Pharma Corp
Zosano Pharma Corp executives and stock owners
Zosano Pharma Corp executives and other stock owners filed with the SEC include:
-
Steven Lo,
Sr. VP of Operations, Pres, CEO & Director -
Dr. Donald J. Kellerman,
VP of Clinical Devel. & Medical Affairs -
Kleanthis Xanthopoulos,
Independent Director -
Kenneth Greathouse,
Independent Director -
Steven Elms,
Independent Director -
Joseph Hagan,
Director -
Linda Grais,
Director -
Thorsten von Stein,
Chief Medical Officer -
Eric Scharin,
Vice President - Technical Operations -
Dushyant Pathak,
Senior Vice President - Business Development -
Christine Matthews,
Chief Financial Officer, Principal Financial Officer -
Steven Lo,
Chief Executive Officer, Director -
John Walker,
Chairman of the Board -
Kristina Warga,
VP & Corp. Controller -
Lu Liu,
VP of Technical Operations -
Jeffrey L. Quillen,
Sec. -
Hayley Lewis,
Sr. VP of Operations -
Christine Matthews,
Chief Financial Officer -
Capital Iv, Lp Aisling Capi...,
-
Winnie Wing Kei Tso,
Chief Financial Officer -
Georgia Erbez,
Interim CFO -
Konstantinos Alataris,
President -
M James Barrett,
Director -
Enterprise Associates 12, L...,
-
Troy Edward Wilson,
Director -
Enterprise Associates 12, L...,
-
Kathy M. Mc Gee,
Director -
Capital Management, Llc Kaz...,
-
Gregory David Kitchener,
Chief Financial Officer -
Elaine Yang,
Director -
Enterprise Associates 12, L...,
-
Realty Trust Inc Bio Med Re...,
-
Laxmi Peri,
Sr. Vice President, Operations -
Hayley Lewis,
See Remarks -
Steve Elms,
Director -
Donald J Kellerman,
VP, Clinical Dev & Med Affairs